Status:
UNKNOWN
DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery
Lead Sponsor:
Vance Thompson Vision
Conditions:
Refractive Surgery
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to standard steroid drop regimen in the contralateral eye following bilateral LASI...
Detailed Description
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to investigate the outcomes of patients undergoing bilateral LASIK surgery with the treatment of a ...
Eligibility Criteria
Inclusion
- Any adult patient who is planned to undergo bilateral LASIK surgery.
- Refractive error between the 2 eyes of 2 Diopters or less
- Willing and able to comply with clinic visits and study related procedures
- Willing and able to sign the informed consent form
Exclusion
- Patients under the age of 18.
- Patients who choose to have monovision after LASIK
- Patients with corneal pathology that may interfere with LASIK outcomes
- Patients who are pregnant (must be ruled out in women of child-bearing age with pregnancy test).
- Active infectious ocular or systemic disease.
- Patients with active infectious ocular or extraocular disease.
- Patients actively treated with local or systemic immunosuppression including systemic corticosteroids.
- Patients with known hypersensitivity to Dexamethasone.
- Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator.
- Patients with a history of ocular inflammation or macular edema.
- Patients with allergy or inability to receive topical antibiotic.
- Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) greater than 1,200 mg/day
- Patients with a corticosteroid implant (i.e. Ozurdex).
- Active or history of chronic or recurrent inflammatory eye disease in either eye
- Ocular pain in either eye
- Proliferative diabetic retinopathy in either eye
- Significant macular pathology detected on macular optical coherence tomography evaluation at the screening visit in either eye
- Laser or incisional ocular surgery during the study period and 6 months prior in either eye
- History of cauterization of the punctum
Key Trial Info
Start Date :
January 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04281862
Start Date
January 23 2020
End Date
May 1 2020
Last Update
February 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vance Thompson Vision ND
West Fargo, North Dakota, United States, 58078